Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study

Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early disc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2024-08, Vol.596, p.217001, Article 217001
Hauptverfasser:	Fletcher, Kylie, Cortellini, Alessio, Ganta, Teja, Kankaria, Roma, Song, Haocan, Ye, Fei, Irlmeier, Rebecca, Debnath, Neha, Saeed, Anwaar, Radford, Maluki, Alahmadi, Asrar, Diamond, Akiva, Hoimes, Christopher, Presley, Carolyn J., Owen, Dwight H., Abou Alaiwi, Sarah, Nassar, Amin H., Lamberti, Giuseppe, Perrone, Fabiana, Buti, Sebastiano, Giusti, Raffaele, Filetti, Marco, Vanella, Vito, Mallardo, Domenico, Sussman, Tamara A., Galetta, Domenico, Kalofonou, Foteini, Daniels, Ella, Ascierto, Paolo A., Pinato, David J., Nebhan, Caroline, Berg, Stephanie, Choueiri, Toni K., Marron, Thomas U., Wang, Yinghong, Naqash, Abdul Rafeh, Johnson, Douglas B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anti-PD-1 therapy Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Female Geriatric population Humans Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immune-related adverse events Immunotherapy Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - mortality Lung Neoplasms - pathology Male Melanoma Melanoma - drug therapy Melanoma - immunology Melanoma - mortality Melanoma - pathology Neoplasms - drug therapy Neoplasms - immunology Neoplasms - mortality Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival Retrospective Studies Time Factors Treatment Outcome Withholding Treatment - statistics & numerical data
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients ≥80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy. We determined response rate, overall survival (OS), and progression-free survival (PFS) in patients who discontinued therapy early (
ISSN:	0304-3835 1872-7980 1872-7980
DOI:	10.1016/j.canlet.2024.217001